8-K: AptarGroup Reports Flat Core Sales in Q1 2025, Adjusted EBITDA Up 3%

AptarGroup's first quarter 2025 results show a slight decrease in reported sales and net income, but an increase in adjusted EBITDA and margin expansion.

Summary

• AptarGroup reported first quarter 2025 sales of $887 million, a 3% decrease compared to the prior year.
• Net income decreased by 5% to $79 million.
• Core sales were flat year-over-year.
• Adjusted EBITDA increased 3% to $183 million, with a margin of 20.7%, representing a 120 basis point expansion.
• Reported earnings per share were $1.17, while adjusted earnings per share were $1.20.
• The Pharma segment saw a 2% increase in reported sales and a 4% increase in core sales.
• Approximately $110 million was returned to shareholders through dividends and share repurchases, including $80 million for share repurchases.
• The company expects second quarter 2025 earnings per share to be in the range of $1.56 to $1.64, excluding certain items.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While sales and net income decreased, adjusted EBITDA increased and the company is optimistic about Q2. The company is also returning capital to shareholders.

Positives

• Adjusted EBITDA increased by 3% and the adjusted EBITDA margin expanded by 120 basis points.
• Aptar Pharma experienced core sales growth of 4%, driven by demand for proprietary drug delivery systems.
• The company returned $110 million to shareholders through dividends and share repurchases.
• Aptar Closures adjusted EBITDA margins improved to approximately 15.8%, expanding by 80 basis points.

Negatives

• Reported sales decreased by 3% to $887 million.
• Reported net income decreased by 5% to $79 million.
• Aptar Beauty's reported sales decreased 7% and core sales were down 3% due to lower prestige fragrance volumes.
• Aptar Closures reported sales decreased 5% from the prior year quarter and core sales decreased 2%.

Risks

• Geopolitical conflicts, including the invasion of Ukraine, could impact demand and increase input costs.
• Cybersecurity threats could impact networks and reporting systems.
• The availability of raw materials and components, particularly from sole-sourced suppliers, is a concern.
• An economic recession could lead to lower demand and asset utilization.
• Fluctuations in foreign currency exchange rates or the effective tax rate could impact financial results.

Future Outlook

Aptar expects to build on its solid start to the year with positive contributions from all three segments, projecting second quarter 2025 earnings per share to be in the range of $1.56 to $1.64, excluding certain items.

Management Comments

• We saw growing demand for our dosing, dispensing and protection technologies across a number of end markets including central nervous system therapeutics, emergency medicines, weight and diabetes management, as well as food, beverage and personal care, said Stephan B. Tanda, Aptar President and CEO.
• We expect to build on our solid start to the year as we head into the second quarter, with positive contributions from all three segments, said Stephan B. Tanda, Aptar President and CEO.

Industry Context

Aptar's focus on drug delivery systems and consumer product dispensing aligns with the growing demand for innovative packaging solutions in the pharmaceutical, beauty, and personal care industries. The company's presence in resilient end markets like medications for chronic diseases and consumer staples positions it well in uncertain economic conditions.

Comparison to Industry Standards

• Aptar's adjusted EBITDA margin of 20.7% is competitive within the packaging industry, but specific comparisons would require benchmarking against peers like Berry Global, Amcor, and Crown Holdings.
• Aptar's growth in the Pharma segment aligns with the broader trend of increased demand for advanced drug delivery systems, similar to companies like West Pharmaceutical Services.
• The company's focus on sustainability and innovative solutions mirrors the strategies of other industry leaders aiming to meet evolving consumer preferences and regulatory requirements.

Stakeholder Impact

• Shareholders will receive a quarterly dividend of $0.45 per share.
• Employees will continue to work in a company that is focused on innovation and growth.
• Customers will benefit from Aptar's continued investment in new products and technologies.
• Suppliers will continue to partner with a company that is a leader in its industry.

Next Steps

• Aptar will hold a conference call on May 2, 2025, to discuss the first quarter results.
• The company will continue to monitor market conditions and execute its growth strategy.
• Aptar will pay a quarterly cash dividend of $0.45 per share on May 22, 2025.

Key Dates

Keywords

AptarGroup, financial results, first quarter, sales, EBITDA, earnings per share, drug delivery systems, share repurchases, dividends, pharmaceutical, beauty, closures